QS Investors’s Aerie Pharmaceuticals AERI Stock Holding History

QS Investors’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,100	Closed	-$100K	–	1692
2019 Q1	$100K	Hold	2,100	–	–	﹤0.01%	1404
2018 Q4	$76K	Hold	2,100	–	–	﹤0.01%	1387
2018 Q3	$129K	Hold	2,100	–	–	﹤0.01%	1325
2018 Q2	$142K	Hold	2,100	–	–	﹤0.01%	1318
2018 Q1	$114K	Hold	2,100	–	–	﹤0.01%	1352
2017 Q4	$125K	Buy	+2,100	New	+$127K	﹤0.01%	1351

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

QS Investors's AERI Position: Q2 2019 in Review

QS Investors sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 2,100 shares — an estimated $100K sold.

QS Investors first reported a position in AERI in Q4 2017 and held it in 6 quarters. The position peaked at $142K in Q2 2018. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

QS Investors reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
QS Investors sold 2,100 Aerie Pharmaceuticals shares in Q2 2019, an estimated $100K.
QS Investors first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 6 quarters.
QS Investors's Aerie Pharmaceuticals position peaked at $142K in Q2 2018.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on QS Investors's 13F filing for Q2 2019, filed 14 Aug 2019.